Benefits and Risks of Transfer from Oral Agents to Insulin in Type 2 Diabetes Mellitus

ISSN： 0114-5916

Source： Drug Safety, Vol.21, Iss.1, 1999-07, pp. : 7-22

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Oral Antidiabetic Agents: Current Role in Type 2 Diabetes Mellitus

By Krentz Andrew J.

Drugs, Vol. 65, Iss. 3, 2005-01 ,pp. : 385-411

Adis International

Access to resources Recommend Favorite

Cost-effectiveness of oral hypoglycaemic agents for the treatment of type 2 diabetes mellitus

By Ward Alexandra O’Brien Judith A Salas Maribel

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 4, 2005-04 ,pp. : 601-608

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and Tolerability of Pioglitazone in Patients with Type 2 Diabetes Mellitus: Comparison with Other Oral Antihyperglycaemic Agents

By Derosa Giuseppe

Drugs, Vol. 70, Iss. 15, 2010-10 ,pp. : 1945-1961

Adis International

Access to resources Recommend Favorite

GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus: Benefits and Challenges

Current Drug Targets, Vol. 17, Iss. 11, 2016-07 ,pp. : 1292-1300

Bentham Science Publishers

Access to resources Recommend Favorite

Optimising Therapy for Insulin-Treated Type 2 Diabetes Mellitus

By Hermann L.

Drugs & Aging, Vol. 17, Iss. 4, 2000-10 ,pp. : 283-294

Adis International

Access to resources Recommend Favorite